本文言語 | English |
---|---|
ジャーナル | Allergology International |
DOI | |
出版ステータス | Accepted/In press - 2020 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
文献へのアクセス
引用スタイル
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future : A follow-up study of the KiHAC cohort. / Sunadome, Hironobu; Matsumoto, Hisako; Tohda, Yuji; Horiguchi, Takahiko; Kita, Hideo; Kuwabara, Kazunobu; Tomii, Keisuke; Otsuka, Kojiro; Fujimura, Masaki; Ohkura, Noriyuki; Iwanaga, Takashi; Hozawa, Soichiro; Niimi, Akio; Kanemitsu, Yoshihiro; Nagasaki, Tadao; Tashima, Noriyuki; Ishiyama, Yumi; Morimoto, Chie; Oguma, Tsuyoshi; Tajiri, Tomoko; Ito, Isao; Ono, Junya; Ohta, Shoichiro; Izuhara, Kenji; Hirai, Toyohiro.
In: Allergology International, 2020.研究成果: Letter › 査読
TY - JOUR
T1 - Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future
T2 - A follow-up study of the KiHAC cohort
AU - Sunadome, Hironobu
AU - Matsumoto, Hisako
AU - Tohda, Yuji
AU - Horiguchi, Takahiko
AU - Kita, Hideo
AU - Kuwabara, Kazunobu
AU - Tomii, Keisuke
AU - Otsuka, Kojiro
AU - Fujimura, Masaki
AU - Ohkura, Noriyuki
AU - Iwanaga, Takashi
AU - Hozawa, Soichiro
AU - Niimi, Akio
AU - Kanemitsu, Yoshihiro
AU - Nagasaki, Tadao
AU - Tashima, Noriyuki
AU - Ishiyama, Yumi
AU - Morimoto, Chie
AU - Oguma, Tsuyoshi
AU - Tajiri, Tomoko
AU - Ito, Isao
AU - Ono, Junya
AU - Ohta, Shoichiro
AU - Izuhara, Kenji
AU - Hirai, Toyohiro
N1 - Funding Information: HM received personal fees from AstraZeneca , Novartis Pharma , GlaxoSmithKline , and Kyorin Pharmaceutical outside the submitted work. YT reports personal fees from Kyorin Pharmaceutical , Teijin Pharma and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Teijin Pharma , Boehringer-Ingelheim , Daiichi Sankyo , Astellas Pharma and Pearl Therapeutics outside the submitted work. KT reports a personal fee from AstraZeneca outside the submitted work. TI reports a personal fee from Kyorin Pharmaceutical and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Boehringer-Ingelheim , Teijin Pharma , Daiichi Sankyo and Pearl Therapeutics outside the submitted work. SH reports personal fees from Astra Zeneca , GlaxoSmithKline , Novartis Pharma , Astellas Pharma , Boehringer-Ingelheim , Sanofi and Kyorin Pharmaceutical . AN reports personal fees from AstraZeneca , MSD , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and research funding from Novartis Pharma , MSD , Nippon Boehringer-Ingelheim and Boston Scientific Japan . TO reports personal fees from AstraZeneca , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and Sanofi and research funding from Fujifilm outside the submitted work. JO is an employee of Shino-Test. KI reports personal fees and a research funding from Shino-Test . The rest of the authors have no conflict of interest.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85097216243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097216243&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2020.10.006
DO - 10.1016/j.alit.2020.10.006
M3 - Letter
C2 - 33218953
AN - SCOPUS:85097216243
JO - Allergology International
JF - Allergology International
SN - 1323-8930
ER -